Floatz logo

Istradefylline

Movement Disorder

Kyowa Kirin, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Movement Disorder cohort.

Asset / SponsorPhaseRating
LEVODOPA
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BBB
TRIMETHOBENZAMIDE
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BB
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2BB
APOMORPHINUM
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BB
LEMBOREXANT
YangPan
Phase 4BB

View all 24 →

Same molecule, other indications

Istradefylline is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
78 / 100
View asset →
TremorDormant
BB
Indicative ·
69 / 100
View asset →
Parkinson diseaseDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →